Ascendis Pharma A/S (NASDAQ:ASND) Receives $187.08 Consensus Price Target from Brokerages

Ascendis Pharma A/S (NASDAQ:ASND) has been given an average rating of “Buy” by the fourteen ratings firms that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a hold recommendation, twelve have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $187.08.

Several analysts have commented on ASND shares. JPMorgan Chase & Co. reduced their price objective on Ascendis Pharma A/S from $174.00 to $165.00 and set an “overweight” rating for the company in a research note on Wednesday, September 4th. The Goldman Sachs Group upped their price target on Ascendis Pharma A/S from $170.00 to $195.00 and gave the stock a “buy” rating in a research note on Tuesday, August 13th. StockNews.com upgraded shares of Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research report on Thursday, September 5th. Citigroup cut their price objective on shares of Ascendis Pharma A/S from $193.00 to $178.00 and set a “buy” rating for the company in a research report on Wednesday, September 4th. Finally, Bank of America boosted their price target on shares of Ascendis Pharma A/S from $165.00 to $175.00 and gave the stock a “buy” rating in a research note on Wednesday, September 4th.

Institutional Trading of Ascendis Pharma A/S

A number of institutional investors have recently bought and sold shares of ASND. Vestal Point Capital LP purchased a new position in shares of Ascendis Pharma A/S in the fourth quarter valued at $78,719,000. Price T Rowe Associates Inc. MD increased its holdings in Ascendis Pharma A/S by 23.3% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,781,926 shares of the biotechnology company’s stock valued at $269,374,000 after acquiring an additional 336,976 shares in the last quarter. Massachusetts Financial Services Co. MA raised its position in Ascendis Pharma A/S by 20.1% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 1,519,219 shares of the biotechnology company’s stock worth $191,346,000 after acquiring an additional 254,749 shares during the last quarter. Acadian Asset Management LLC lifted its holdings in shares of Ascendis Pharma A/S by 1,461.1% in the first quarter. Acadian Asset Management LLC now owns 250,492 shares of the biotechnology company’s stock valued at $37,849,000 after purchasing an additional 234,446 shares in the last quarter. Finally, Avoro Capital Advisors LLC grew its position in shares of Ascendis Pharma A/S by 5.8% in the second quarter. Avoro Capital Advisors LLC now owns 4,196,661 shares of the biotechnology company’s stock valued at $572,341,000 after purchasing an additional 229,995 shares during the last quarter.

Ascendis Pharma A/S Stock Performance

NASDAQ ASND opened at $113.81 on Friday. Ascendis Pharma A/S has a one year low of $85.29 and a one year high of $161.00. The firm has a market cap of $6.63 billion, a PE ratio of -11.84 and a beta of 0.63. The firm’s fifty day moving average is $132.78 and its two-hundred day moving average is $137.00.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.